<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2014.515121</article-id><article-id pub-id-type="publisher-id">IJCM-48589</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>MEDICINE &amp; HEALTHCARE</subject></subj-group></article-categories><title-group><article-title>Role of Serum Procalcitonin Level in Differentiating between Pulmonary Tuberculosis and Community-Acquired Pneumonia</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohammad</surname><given-names>Shameem</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mazhar</surname><given-names>Alam</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shagufta</surname><given-names>Moin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rakesh</surname><given-names>Bhargava</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zuber</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jamal</surname><given-names>Akhtar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Biochemistry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India</addr-line></aff><aff id="aff1"><addr-line>Department of Tuberculosis and Respiratory Diseases, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP 202002, India</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>drshameem123@gmail.com(MS)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>08</month><year>2014</year></pub-date><volume>05</volume><issue>15</issue><fpage>902</fpage><lpage>909</lpage><history><date date-type="received"><day>20</day>	<month>May</month>	<year>2014</year></date><date date-type="rev-recd"><day>19</day>	<month>June</month>	<year>2014</year>	</date><date date-type="accepted"><day>18</day>	<month>July</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
	Pulmonary Tuberculosis
(PTB) and Community-Acquired Pneumonia (CAP) are common causes of consolidation
patch in chest radiograph. Sputum Z-N staining is positive in 30% to 60% cases
only and sputum examination has poor yield in CAP. This study aimed to assess
the value of serum Procalcitonin (PCT) levels in patients with Pulmonary Tuberculosis
(PTB) and Community-Acquired Pneumonia (CAP). Patients with new opacity in
chest radiograph were included in the study. Serum sample were taken at
admission and stored. Patient’s diagnosis were confirmed and categorized into
pulmonary TB group (32) and community-acquired pneumonia group (23). Their mean
PCT level was compared with mean PCT level of 25 controls. Serum procalcitonin levels
were found to be significantly elevated in patients of community-acquired
pneumonia as compared to patients of pulmonary tuberculosis. In presence of
consolidation in x-ray chest, increased level of serum procalcitonin might be
used to differentiate pulmonary tuberculosis from community-acquired pneumonia.
High level of serum procalcitonin was associated with high mortality rate in community-acquired
pneumonia patients.
</p></abstract><kwd-group><kwd>Procalcitonin</kwd><kwd> Tuberculosis</kwd><kwd> Community-Acquired Pneumonia</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>There are large number of patients presenting to pulmonary medicine OPD with fever, cough and consolidation in x-ray chest. Sometimes, clinical symptoms are minimal but there is extensive consolidation in chest x-ray. Diagnosis of such patient may vary from community-acquired pneumonia, pulmonary tuberculosis to Interstitial Lung Diseases. In pulmonary diseases, yield of microbiological investigation is low and radiological findings are quite overlapping. Sometimes, this creates problem in deciding whether the problem is infective or non-in- fective leading to injudicious prescriptions of antibiotics or delayed treatments. This needs invasive methods of investigations, which are associated with increased incidence of complications. Pulmonary tuberculosis and pneumonia are the most common infective disease requiring admission in pulmonary medicine ward. There are 9 million new cases of pulmonary tuberculosis worldwide every year and 30% to 60% of them are smear negative tuberculosis. This leads to delay in treatment and extra investigation to rule out other diagnoses. Sputum Z-N staining is the first and most rapid investigation for diagnosis of pulmonary tuberculosis. But it is positive in only 50% to 70% of active pulmonary tuberculosis. Yield of sputum Z-N staining is especially low in, children, elderly, diabetes mellitus, HIV and other immune-compromised patients. Primary progressive pulmonary tuberculosis also has lower sputum positivity rate. Sputum culture for mycobacterium is time-taking and costly and not easily available, bronchial-lavage is an invasive method and it requires expertise. Often elderly patients of pneumonia presents with low grade fever and a small amount of sputum production and poor responses to antibiotics. 10% of CAP patients develop non-responding CAP (NCAP) [<xref ref-type="bibr" rid="scirp.48589-ref1">1</xref>] leading to difficulties in differentiating pneumonia from tuberculosis. With this concern, there is a need of alternate diagnostic test.</p></sec><sec id="s2"><title>2. Patients and Study Design</title><p>This was planned as prospective study. This study was undertaken in the Department of Tuberculosis And Respiratory Diseases and Department of Biochemistry, Jawaharlal Nehru Medical College, Aligarh Muslim Univer- sity, Aligarh during the period 2011-2013. The subjects were selected from the patients attending OPD or ad- mitted in IPD of Tuberculosis and Respiratory Diseases. The patients of pulmonary tuberculosis were diag- nosed on the basis of sputum Z-N staining, Sputum culture for Mycobacterium Tuberculosis and Chest x-ray. Patients of community-acquired pneumonia were diagnosed on the basis of History, Examination and Investi- gations e.g. fever, cough, consolidation in chest x-ray, sputum gram staining, sputum culture, blood culture and resolution of consolidation after recommended course of antibiotics (As per American Thoracic Society Guide- line).</p><p>All the patients of pulmonary tuberculosis and CAP were further evaluated for sepsis and organ dysfunction and classified into with sepsis or without sepsis as per Sepsis Survival Campaign Guidelines 2012. Patients of CAP were assessed for severity by using CURB-65 Scoring and Pneumonia Severity Index and severity score was assigned. Complications and mortality were recorded.</p></sec><sec id="s3"><title>3. Investigations Done for Diagnosis and Severity Assessment</title><p>Investigations done for confirmation of diagnosis and assessing severity were chest x-ray, Haemogram, Renal function test, Liver function test, Blood sugar, Serum electrolyte, Arterial Blood Gas Analysis, Sputum Z-N Staining, Sputum culture for Mycobacterium Tuberculosis, Sputum culture for pyogenic bacteria, Blood culture, ELISA for HIV</p><sec id="s3_1"><title>3.1. Selection of Subjects</title><p>The protocol used for the study was in accordance with guidelines of institutional ethical committee. Seventy patients were included in this study. Patients attending OPD or admitted in the IPD of Tuberculosis and Respiratory Diseases JNMCH during 2011 to 2013, with consolidation or cavity in chest x-ray were enrolled. Blood samples were taken before starting antibiotics or anti-tuberculosis treatment. Finally, 55 samples (32 pulmonary TB and 23 CAP) were tested for procalcitonin level. 15 Samples were discarded either because of hemolysis or patient had not taken treatment as advised. 25 samples were taken as control for comparison from age and sex matched healthy volunteers. The subjects were divided in the following groups.</p><p>• PTB: Pulmonary Tuberculosis Group (32 patients);</p><p>• CAP: Community-Acquired Pneumonia Group (23 patients);</p><p>• Control: Apparently healthy age and sex matched volunteers.</p></sec><sec id="s3_2"><title>• 3.2. Exclusion Criteria</title><p>• Patients with any infection other than pulmonary tuberculosis and CAP;</p><p>• CAP along with Carcinoma of lung.</p></sec><sec id="s3_3"><title>3.3. Collection of Blood and Isolation of Serum</title><p>Blood samples were taken after informed written consent from all the study group subjects on first day before starting treatment with a disposable syringe &amp; needle, under all aseptic conditions. Serum was separated by centrifuging the blood at 300 rpm for 20 minutes. Samples were stored in aliquots at −20˚C until assayed.</p></sec><sec id="s3_4"><title>3.4. Estimation of Serum Procalcitonin</title><p>It was based on the principle of ELISA. This assay employs an antibody specific for human procalcitonin coated on a 96-well plate. Standards and samples are pipetted into the wells and procalcitonin present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human procalcitonin antibody added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of procalcitonin bound. The Stop solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.</p></sec><sec id="s3_5"><title>3.5. Assay Procedure</title><p>100 &#181;l standard or sample was added to each well. Well covered and incubated over night at 4˚C with gentle shaking. The solution was discarded and washed 4 times with 1&#215; wash solution. After the last wash, any remaining wash buffer was removed by decanting. The plate was inverted and blotted against clean blotting paper. 100 &#181;L of 1x prepared biotinylated antibody was added to each well and incubated for 1 hr at room temperature with gentle shaking. The solution was discarded and the wash was repeated as described earlier. 100 &#181;L streptavudine solutions was added to each well, and incubated for 45 minute at room temperature with gentle shaking. 100 &#181;L of TMB One-Step substrate reagent was added to each well and incubated for 30 minute at room temperature in dark with gentle shaking. 50 &#181;L of stop solution was added to each well and read immediately.</p></sec><sec id="s3_6"><title>3.6. Calculation of Results</title><p>We Calculated the Mean absorbance for each set standards, controls and samples, and subtract the average zero standard optical density. The Standard curve was plotted by using Sigma plot software, with standard concentration on x axis and absorbance on the y-axis. The best-fit straight line was drawn through the standard points Standard level of procalcitonin was plotted at 450 nm (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s3_7"><title>3.7. Sensitivity of the Kit</title><p>The minimum detectable dose of procalcitonin is typically less than 30 pg/ml.</p></sec><sec id="s3_8"><title>3.8. Statistical Analysis</title><p>SPSS version 16 software package was used to analyze the data. The data is reported as mean &#177; SD. The results were statistically analyzed using ANOVA and Students t-test. P ≤ 0.05 was considered as statistically significant.</p></sec></sec><sec id="s4"><title>4. Observation and Results</title><p>The present study was conducted on subjects attending OPD or IPD of Tuberculosis and Respiratory Diseases, Jawaharlal Nehru Medical College, AMU, Aligarh from 2011 to 2013. Analysis of Blood sample for serum procalcitonin was done in Department of Biochemistry, JNMCH, Aligarh. This study includes three groups of</p><fig id="fig1"><label>Figure 1</label><caption><p> Standard procalcitonin concentration (pg/ml)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\4-2100848x\1d8f93fa-5569-49f9-9ccd-5dbf0da74978.png"/></fig><p>participants, Pulmonary Tuberculosis (PTB), Community-Acquired Pneumonia (CAP) and Controls. Each group is matched for age, sex and comorbidity. There are 32 patients (41% Male, 59% Female) in PTB group, mean age 48.59 &#177; 17.92 (Male 50.31 &#177; 16.44, Female 46.07 &#177; 19.5) years, 23 patients (35% Male, 65% Female ) in CAP group, mean age 57.69 &#177; 14.93 (Male 57.26 &#177; 15.26, Female 58.37 &#177; 15.26) years and 25 (40% Male, 60% Female) voluntary participants in control group, mean age 44.88 &#177; 14.26 (Male 44.46 &#177; 15.14, Female 45.5 &#177; 14.45) years. In the pulmonary TB group, three were HIV positive, four had diabetes mellitus, three had systemic hypertension, 2 had COPD, and three had malnutrition and anemia. In the CAP group two were HIV positive. Four had diabetes mellitus, three had systemic hypertension, two had chronic kidney disease and four had COPD. On statistical analysis there was no significant difference in these conditions.</p><p>Of the 23 patients in the CAP group, four had a positive sputum culture for Streptococcus pneumoniae, one had positive blood culture for S. pneumoniae, and one had a positive sputum culture for Klebsiella pneumonie. The hospital mortality was 6.35 (2/32) in the PTB group and 21.7% (5/23) in the CAP group.</p></sec><sec id="s5"><title>5. Data Analysis</title><p>Data was analyzed using SPSS-16 software. ANOVA was used to analyze the difference in three study groups and independent t-test used to compare PCT levels in sepsis and non sepsis groups. Mean PCT levels in pulmonary tuberculosis, CAP and Controls were compared using ANOVA. On Analysis of Variance (ANOVA) testing, there was a significant difference in serum PCT levels at P &lt; 0.05 for controls, pulmonary tuberculosis and CAP [F(2, 77) = 33.962., P = 0.000] (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Mean procalcitonin levels were 42.664 pg/ml in controls and 194.834pg/ml in Pulmonary tuberculosis patients and 821.317 pg/ml in community-acquired pneumonia group (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Mean PCT levels were also calculated in males and females in each group and they were compared for difference by using independent t-test. There was no significant difference in serum procalcitonin levels in males and females in any groups (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Further, Post hoc comparisons using the Tukey HSD test indicate that the mean serum PCT for control group (Mean = 42.664, SD = &#177;8.0205 pg/ml) is not significantly different than those with pulmonary tuberculosis group (Mean = 194.834, SD = &#177;145.2233 pg/ml) with P value of 0.235, Mean serum PCT for control group (M = 42.664, SD = &#177;8.0205 pg/ml) was significantly different than those in CAP group (M = 821.317, SD = &#177;626.6993 pg/ml) with P value of 0.000 and mean serum PCT level in pulmonary tuberculosis group (Mean = 194.834, SD = &#177;145.2233 pg/ml) is significantly different than those in CAP group (Mean = 821.317, SD = 626.6993 pg/ml) with P value of 0.000. Taken together, these results suggest that PCT in CAP is significantly increased than those in pulmonary tuberculosis and controls. There is no significant difference in PCT level of pulmonary tuberculosis and controls. Patients in pulmonary tuberculosis and CAP group were further categorized into patient with sepsis and without sepsis and analysis of mean was done using independent t-test. In pulmonary tuberculosis group—8 patient were having sepsis and 25 were not having sepsis. Mean PCT level in pulmonary TB with sepsis group (377.912 &#177; 157.3 pg/ml) was significantly higher than those in non sepsis group (123.202 &#177; 40.487 pg/ml) with P value of 0.001 as shown in (<xref ref-type="table" rid="table3">Table 3</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>In CAP group—9 were in sepsis and 14 were not having sepsis. Mean PCT level in CAP with sepsis group (1334.3 &#177; 737.12) was significantly higher than those in non sepsis group (491.571 &#177; 176.19 pg/ml) with P value</p><table-wrap id="table1"  position="float"><object-id pub-id-type="pii">Table 1</object-id><label>Table 1</label><caption><p>. Procalcitonin levels (pg/ml) in different study groups</p></caption><table><thead><tr><th align="center" valign="middle" >Groups</th><th align="center" valign="middle" >N</th><th align="center" valign="middle" >Mean PCT Level (Pg/ml)</th><th align="center" valign="middle" >SD</th></tr></thead><tbody><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >42.664</td><td align="center" valign="middle" >&#177;8.0204</td></tr><tr><td align="center" valign="middle" >Pulmonary  Tuberculosis</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >194.834</td><td align="center" valign="middle" >&#177;145.2233</td></tr><tr><td align="center" valign="middle" >CAP</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >821.317</td><td align="center" valign="middle" >&#177;626.699</td></tr></tbody></table></table-wrap><table-wrap id="table2"  position="float"><object-id pub-id-type="pii">Table 2</object-id><label>Table 2</label><caption><p>. Mean PCT levels in males and females in different study groups</p></caption><table><thead><tr><th align="center" valign="middle" >Groups</th><th align="center" valign="middle" >Male</th><th align="center" valign="middle" >Female</th><th align="center" valign="middle" >P value</th></tr></thead><tbody><tr><td align="center" valign="middle" >Pulmonary Tuberculosis</td><td align="center" valign="middle" >192.984 &#177; 167.131 (n = 19)</td><td align="center" valign="middle" >197.538 &#177; 112.113 (13)</td><td align="center" valign="middle" >0.259</td></tr><tr><td align="center" valign="middle" >CAP</td><td align="center" valign="middle" >818.887 &#177; 553.330 (n = 15)</td><td align="center" valign="middle" >825.875 &#177; 788.655 (n = 8)</td><td align="center" valign="middle" >0.265</td></tr><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >41.056 &#177; 7.6894 (n = 15)</td><td align="center" valign="middle" >45.522 &#177; 8.2318 (n = 10)</td><td align="center" valign="middle" >0.827</td></tr></tbody></table></table-wrap><table-wrap id="table3"  position="float"><object-id pub-id-type="pii">Table 3</object-id><label>Table 3</label><caption><p>. Mean PCT levels in patients of PTB and CAP with and without sepsis</p></caption><table><thead><tr><th align="center" valign="middle" >Pulmonary Tuberculosis Group</th><th align="center" valign="middle" >123.202 &#177; 40.487 (n = 23)</th><th align="center" valign="middle" >377.912 &#177; 157.3 (n = 9)</th><th align="center" valign="middle" >0.001</th></tr></thead><tbody><tr><td align="center" valign="middle" >Community-Acquired Pneumonia Group</td><td align="center" valign="middle" >491.571 &#177; 176.19 (n = 14)</td><td align="center" valign="middle" >1334.3 &#177; 737.12 (n = 9)</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><fig id="fig2"><label>Figure 2</label><caption><p> Mean PCT level (pg/ml) in study groups</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\4-2100848x\279cc122-97a4-48c2-9575-d891919cbc7f.png"/></fig><p>&lt; 0.05 as can be seen in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</p><p>Patients in CAP group were further categorized into those survived and expired. Mean PCT level were 548.778 &#177; 232.2371 pg/ml and 1802.3 &#177; 1802.3 pg/ml (mean &#177; SD) respectively, and there was significant difference with P value 0.004 as depicted in (<xref ref-type="table" rid="table4">Table 4</xref>, <xref ref-type="fig" rid="fig5">Figure 5</xref>).</p></sec><sec id="s6"><title>6. Discussion</title><p>Pulmonary Tuberculosis (TB) is a major global health problem. Each year, there are around 9 million new cases of TB, and close to 2 million people die from the disease. India and China alone account for 35% of all cases. Global scenario of pulmonary tuberculosis has markedly changed with the rise of HIV infection (Global TB Report 2011). Pulmonary tuberculosis is a granulomatous infectious disease of lung caused by Mycobacterium Tuberculosis. There are varied presentations of pulmonary tuberculosis, Secondary pulmonary tuberculosis being the most common. Sputum culture for Mycobacterium tuberculosis is the gold standard for diagnosis but sputum Z-N staining is most commonly used. Sputum Z-N staining is negative in 30% - 50% of patients (ATS</p><fig id="fig3"><label>Figure 3</label><caption><p> Mean PCT level (pg/ml) in male and female in different groups</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\4-2100848x\198b2189-98c7-4924-90fe-34ded82825e4.png"/></fig><fig id="fig4"><label>Figure 4</label><caption><p> Mean PCT levels in patients of PTB and CAP</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\4-2100848x\f86dee2a-4437-43ed-a438-f67ea465b3f5.png"/></fig><fig id="fig5"><label>Figure 5</label><caption><p> Mean PCT level in CAP patients in survived and expired patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\4-2100848x\4c432fd2-4c2c-4077-bdea-92e7f352ab99.png"/></fig><table-wrap id="table4"  position="float"><object-id pub-id-type="pii">Table 4</object-id><label>Table 4</label><caption><p>. PCT Levels in survived and expired group of CAP</p></caption><table><thead><tr><th align="center" valign="middle" >Group</th><th align="center" valign="middle" >Survived</th><th align="center" valign="middle" >Expired</th><th align="center" valign="middle" >P value</th></tr></thead><tbody><tr><td align="center" valign="middle" >Community-Acquired Pneumonia Group</td><td align="center" valign="middle" >548.778 &#177; 232.2371 (n = 18)</td><td align="center" valign="middle" >1802.3 &#177; 1802.3 (n = 5)</td><td align="center" valign="middle" >0.004</td></tr></tbody></table></table-wrap><p>and CDC 2003). These sputum negative patients can be differentiated from community-acquired pneumonia by other modality of investigation (sputum culture for Mycobacterium, Bronchial lavage or Histopathological examination) which are time taking, costly and require specialist.</p><p>Community-acquired pneumonia is acute inflammation of lung parenchyma. Streptococcus pneumonae and Haemophilus influenzae are the most common cause of CAP [<xref ref-type="bibr" rid="scirp.48589-ref2">2</xref>] . Community-Acquired Pneumonia (CAP) is the third leading cause of death worldwide. Its incidence is on rise with increasing life expectancy. It mainly affects under five children and elderly &gt;65 year age group. Hospitalization, complication and mortality are high in both the age group [<xref ref-type="bibr" rid="scirp.48589-ref3">3</xref>] . Almost 20% of the hospitalized patients need intensive care admission [<xref ref-type="bibr" rid="scirp.48589-ref4">4</xref>] (Kaplan V et al., 2002) and 10% of CAP progress to non resolving pneumonia [<xref ref-type="bibr" rid="scirp.48589-ref1">1</xref>] .</p><p>Procalcitonin is a peptide precursor of calcitonin. It is normally synthesized in parafollicular cells of thyroid gland but in systemic inflammation and sepsis it is also synthesized by parenchymal tissue specially, lung, liver, kidney and adrenal gland. It is not detectable in healthy individuals (&lt;10 pg/ml). In various studies it has been found to be elevated in bacterial infection and sepsis. It has also been found to be elevated in Systemic Inflammatory Response Syndrome (SIRS) but to a lower degree than sepsis.</p><p>From the above literature we infer that there is need of alternate diagnostic investigation to differentiate sputum smear negative pulmonary tuberculosis from non-responding community-acquired pneumonia. Further, patients of CAP require severity assessment and prognosis assessment. PSI and CURB-65 severity assessment scores are somewhat limited by practicality and risk of miscalibration due to different patient populations and, therefore, have only moderate operational characteristics [<xref ref-type="bibr" rid="scirp.48589-ref5">5</xref>] . Therefore, there is need for new severity assessment parameter. With this background we have compared serum PCT level in pulmonary tuberculosis and CAP.</p><p>In community-acquired pneumonia mean serum procalcitonin level is significantly elevated as compared to pulmonary tuberculosis. Therefore, elevated procalcitonin level in presence of consolidation in chest x-ray may be useful in detection of bacterial pneumonia and can be used to differentiate between pulmonary tuberculosis and community acquired pneumonia. In our study mean serum PCT level was 194.834 &#177; 145.2233 pg/ml in pulmonary tuberculosis group and mean serum PCT level in community-acquired pneumonia group was 821.317 &#177; 6262.999 pg/ml. Difference between two values was significant. Similar results were also reported by K. Nyamande and U.G. Lalloo. They also found a significant difference in serum PCT level in pulmonary tuberculosis (4.164 &#177; 1.197 ng/ml) as compared to community-acquired pneumonia (19.479 &#177; 5.640 ng/ml). The serum level of PCT measured by K. Nayamande and U.G. Lallo was much higher than our study. In “Procalcitonin-Guided Antibiotic Therapy and Hospitalization in Patients with Lower Respiratory Tract Infections” (Pro- HOSP) study, Schuetz P. et al. (2011) found that serum PCT of &gt;0.5 ng/ml is associated with severe sepsis and high mortality rate [<xref ref-type="bibr" rid="scirp.48589-ref6">6</xref>] . Ugajin M et al (2011) studied PCT level in pulmonary tuberculosis patients and Pneumonia patients he also reported significant difference in PCT level in the two group (mean PCT in PTB group was 210 &#177; 490 pg/ml and in Pneumonia group was 4100 &#177; 8680 pg/ml) [<xref ref-type="bibr" rid="scirp.48589-ref7">7</xref>] . In a study by G.K. Schleicher et al. on Pneumococcal pneumonia and pulmonary tuberculosis in HIV positive patients mean PCT level was 1030 pg/ml and 19050 pg/ml in the two group, respectively, with P value of &lt;0.0005 [<xref ref-type="bibr" rid="scirp.48589-ref8">8</xref>] .</p></sec><sec id="s7"><title>7. Conclusions</title><p>The present study entitled “Comparison of Serum Procalcitonin Level in Pulmonary Tuberculosis and Community-Acquired Pneumonia” is a prospective study. The study was conducted in Department of Tuberculosis and Respiratory Diseases and Department of Biochemistry, Jawaharlal Nehru Medical College, Aligarh during 2011-2013, on 80 subjects (32 Pulmonary Tuberculosis, 23 CAP and 25 Control). The aim of study was to compare serum procalcitonin level in pulmonary tuberculosis and CAP and its role as prognostic marker in CAP.</p><p>• Serum procalcitonin levels were found to be significantly elevated in patients of community-acquired Pneumonia as compared to patients of pulmonary tuberculosis.</p><p>In presence of consolidation in chest x-ray, increased level of serum procalcitonin may be used to differentiate pulmonary tuberculosis from community-acquired pneumonia. High level of serum procalcitonin is associated with high mortality rate in community-acquired pneumonia patients. This study merits further evaluation.</p></sec><sec id="s8"><title>NOTES@endMarkP#wang#_title:ep!!!</title><p></p><disp-formula id="scirp.48589-formula2309"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://file.scirp.org/Html/htmlimages\4-2100848x\1828baf3-c27e-4ab3-b361-59e79b46694e.png"/></disp-formula><p><sup>*</sup>Corresponding author.</p><p></p></sec></body><back><ref-list><title>References</title><ref id="scirp.48589-ref1"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>MENENDEZ</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> PERPINA</surname><given-names> M. </given-names></name>,<name name-style="western"><surname> TORRES</surname><given-names> A. </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>MENENDEZ, R., PERPINA, M. AND TORRES, A.  EVALUATION OF NON-RESOLVING AND PROGRESSIVE PNEUMONIA</article-title><source> SEMINARS IN RESPIRATORY INFECTIONS</source><volume> 18</volume>,<fpage> 103</fpage>-<lpage>111</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.48589-ref2"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>LIM</surname><given-names> W.S.</given-names></name>,<name name-style="western"><surname> MACFARLANE</surname><given-names> J.T.</given-names></name>,<name name-style="western"><surname> BOSWELL</surname><given-names> T.C.</given-names></name>,<name name-style="western"><surname> ET AL. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>STUDY OF COMMUNITY-ACQUIRED PNEUMONIA AETIOLOGY (SCAPA) IN ADULTS ADMITTED TO HOSPITAL: IMPLICATIONS FOR MANAGEMENT GUIDELINES</article-title><source> THORAX</source><volume> 56</volume>,<fpage> 296</fpage>-<lpage>301</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1136/THORAX.56.4.296</pub-id></mixed-citation></ref><ref id="scirp.48589-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>LIEBERMAN</surname><given-names> D.</given-names></name>,<name name-style="western"><surname> LIEBERMAN</surname><given-names> D.</given-names></name>,<name name-style="western"><surname> SCHLAEFFER</surname><given-names> F. </given-names></name>,<name name-style="western"><surname> PORATH</surname><given-names> A. </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>COMMUNITY-ACQUIRED PNEUMONIA IN OLD AGE: A PROSPECTIVE STUDY OF 91 PATIENTS ADMITTED FROM HOME</article-title><source> AGE AGEING</source><volume> 26</volume>,<fpage> 69</fpage>-<lpage>75</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1093/AGEING/26.2.69</pub-id></mixed-citation></ref><ref id="scirp.48589-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>KAPLAN</surname><given-names> V.</given-names></name>,<name name-style="western"><surname> ANGUS</surname><given-names> D.C.</given-names></name>,<name name-style="western"><surname> GRIFFIN</surname><given-names> M.F.</given-names></name>,<name name-style="western"><surname> CLERMONT</surname><given-names> G.</given-names></name>,<name name-style="western"><surname> SCOTT</surname><given-names> W.R. </given-names></name>,<name name-style="western"><surname> LINDE-ZWIRBLE</surname><given-names> W.T. </given-names></name>,<etal>et al</etal>. (<year>2002</year>)<article-title>HOSPITALIZED COMMUNITY-ACQUIRED PNEUMONIA IN THE ELDERLY: AGE- AND SEX-RELATED PATTERNS OF CARE AND OUTCOME IN THE UNITED STATES</article-title><source> AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE</source><volume> 165</volume>,<fpage> 766</fpage>-<lpage>772</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1164/AJRCCM.165.6.2103038</pub-id></mixed-citation></ref><ref id="scirp.48589-ref5"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SCHUETZ</surname><given-names> P.</given-names></name>,<name name-style="western"><surname> KOLLER</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> CHRIST-CRAIN</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> ET AL. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>PREDICTING MORTALITY WITH PNEUMONIA SEVERITY SCORES: IMPORTANCE OF MODEL RECALIBRATION TO LOCAL SETTINGS</article-title><source> EPIDEMIOLOGY AND INFECTION</source><volume> 136</volume>,<fpage> 1628</fpage>-<lpage>1637</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1017/S0950268808000435</pub-id></mixed-citation></ref><ref id="scirp.48589-ref6"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SCHUETZ</surname><given-names> P.</given-names></name>,<name name-style="western"><surname> SUTER-WIDMER</surname><given-names> I.</given-names></name>,<name name-style="western"><surname> CHAUDRI</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> CHRIST-CRAIN</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> ZIMMERLI</surname><given-names> W. </given-names></name>,<name name-style="western"><surname> MUELLER</surname><given-names> B. FOR THE PROCALCITONIN-GUIDED ANTIBIOTIC THERAPY </given-names></name>,<name name-style="western"><surname> HOSPITALISATION IN PATIENTS WITH LOWER RESPIRATORY TRACT INFECTIONS </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>PROHOSP</year>)<article-title>STUDY GROUP (2011) PROGNOSTIC VALUE OF PROCALCITONIN IN COMMUNITY-ACQUIRED PNEUMONIA</article-title><source> EUROPEAN RESPIRATORY JOURNAL</source><volume> 37</volume>,<fpage> 384</fpage>-<lpage>392</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1183/09031936.00035610</pub-id></mixed-citation></ref><ref id="scirp.48589-ref7"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>UGAJIN</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> MIWA</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> SHIRAI</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> OHBA</surname><given-names> H.</given-names></name>,<name name-style="western"><surname> EIFUKU</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> NAKAMURA</surname><given-names> H.</given-names></name>,<name name-style="western"><surname> SUDA</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> HAYAKAWA</surname><given-names> H. </given-names></name>,<name name-style="western"><surname> CHIDA</surname><given-names> K. </given-names></name>,<etal>et al</etal>. (<year>2011</year>)<article-title>USEFULNESS OF SERUM PROCALCITONIN LEVELS IN PULMONARY TUBERCULOSIS</article-title><source> EUROPEAN RESPIRATORY JOURNAL</source><volume> 37</volume>,<fpage> 371</fpage>-<lpage>375</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1183/09031936.00011910</pub-id></mixed-citation></ref><ref id="scirp.48589-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SCHLEICHER</surname><given-names> G.K.</given-names></name>,<name name-style="western"><surname> HERBERT</surname><given-names> V.</given-names></name>,<name name-style="western"><surname> BRINK</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> MARTIN</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> MARAJ</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> GALPIN</surname><given-names> J.S. </given-names></name>,<name name-style="western"><surname> FELDMAN</surname><given-names> C. </given-names></name>,<etal>et al</etal>. (<year>2005</year>)<article-title>PROCALCITONIN AND C-REACTIVE PROTEIN LEVELS IN HIV-POSITIVE SUBJECTS WITH TUBERCULOSIS AND PNEUMONIA</article-title><source> EUROPEAN RESPIRATORY JOURNAL</source><volume> 25</volume>,<fpage> 688</fpage>-<lpage>692</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1183/09031936.05.00067604</pub-id></mixed-citation></ref></ref-list></back></article>